J.M. Hernánz

Leishmaniasis

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity

Protective immune mechanisms in helminth infection

ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice

Cutaneous leishmaniasis

Psoriasis

PKDL and Other Dermal Lesions in HIV Co-infected Patients with Leishmaniasis: Review of Clinical Presentation in Relation to Immune Responses

Cutaneous Leishmaniasis following Local Trauma: A Clinical Pearl

TFOS DEWS II Management and Therapy Report

Leishmaniasis

Leishmania and human immunodeficiency virus coinfection: the first 10 years

Demodicosis and rosacea: Epidemiology and significance in daily dermatologic practice

Requirements for the development of IL‐4‐producing T cells during intestinal nematode infections: what it takes to make a Th2 cell in vivo

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

Drug Resistance in Leishmaniasis

Granulomatous rosacea in a child infected with the human immunodeficiency virus

Rosacea-Like Demodicosis in an HIV-Positive Child

Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents

Leishmania infection occurring in herpes zoster lesions in an HIV-positive patient

Leishmania infection occurring in herpes zoster lesions in an HIV-positive patient

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos